BIBLIOGRAFIA

1. ZINBERG,N.E.: Drug, set and setting: the basis for controlled intoxicant use. New Haven, Yale University Press, 1984.

2. MARK & IRVING: Violence and the brain. 1970; cited in:

3. PATTERSON,D.: The violence of psychosurgery. New Scientist, 8 febr. 1979, 374-376.

4. LIDBERG,L.TUCK,J.R.,ASBERG,M., SCALIA-TOMBA,G.P. & BERTILSSON,L.: Homicide, suicide and CSF 5-HIAA. Acta Psychiatrica Scandinavica, 1985, 71(3):230-236.

5. TABAKOFF,B.,HOFFMAN,P.L. & PETERSEN,R.C.: Advances in neurochemistry, a leading edge of alcohol research. Alcohol health & Research world, 1990, 14(2):138-143

6. SHUSTER,L.: Genetics of responses to drugs of abuse. Int.J.Addictions, 25(1A)57-79 (1990-91)

7. ERIKSSON,P.S., RöNNBäCK,L., & HANSSON,E.: Do persistent morphine effects involve interactions with the genome? Drug and Alcohol Dependence, 1989, 24;39-43.

8. LINDESMITH,A.: Can chimpansees become addicts? J..Compar.Psychol. 39; 1946

9. SPRAGG,S.D.S.: Morphine addiction in Chimpansees. Comparative Psychology Monograph 15, no 7, 1940

10. DE KORT,M.: Medische professionals en hùn drugs. Verzorging, 4 (1989) 2:20-32

11. MERLIN, M.D.: On the trail of the ancient opium poppy. Associated University Presses, Cranbury, 1984.

12. BERRIDGE,V. & RAWSON,N.S.B.: Opiate use and legislative control: a nineteenth century case study. Social Science and Medicine, 1979; 13A(3): 351-363.

BERRIDGE,V.& EDWARDS,G.: Opium and the people. Allan Lane, London, 1981

BERRIDGE,V.: Opium. In:Polak,F.& Miks,T.: Dokters en dope. NIAD, 1994

13. W.ELLIOTT, cit. in: JUDSON,H.F.: Heroin addiction in Britain. Harcourt Brace Jovanovich, New York, 1974

14. MUSTO,D.: The American disease. Yale University Press, New Haven, 1973

15. TAYLOR,A.H.: American diplomacy and the narcotics traffic, 1900-1939. Duke University Press, 1969.

16. McCOY, A.F.: The politics of heroin: CIA complicity in the global drug trade. Lawrence Hill Books, Brooklyn N.Y., 1991

17. DRUMMOND D.C. et al.: Chlordiazepoxide vs. methadone in opiate withdrawal: a preliminary double blind trial. Drug and Alcohol dependence, 23 (1989) 63-71

18. ARIF,A. & WESTERMEYER,J.: Methadone in the management of opioid dependence. Programs and policies around the world. New York, Praeger, 1990

19. DOLE, V.P. & M.E.NYSWANDER: Rehabilitation of heroin addicts after blockade with methadone. New York State Journal of Medicine, 1 augustus 1966

20. DOLE,V.P.,M.E.NYSWANDER, M.J.CREEK: Narcotic blockade Arch.Intern.Med., 1966, 118.

21. DOLE,V.P.,M.E.NYSWANDER: The use of methadone for Narcotic Blockade. Br.J.Addict. 1968, 63;55-57.

22. GEARING,F.R.: Evaluation of methadone maintenance program. Intern.J.Addict.,1970,5;517.

23. GEARING,F.R. & M.D.SCHWEITZER: An epidemiologic evaluation of long-term methadone maintenance treatment for heroin. Am.J. of Epidemiology, 1974, vol.100.

24. VOSSENBERG,P.: Methadon informatie, CAD De IJsselstreek, 1989.

25. TRIMBOS,C.J.B.J.: De methadon-onderhoudsbehandeling van heroine-verslaving. Ned.Tijdschr.Geneesk. 1971,115;7.

26. MADDUX,J.F.& C.L.BOWDEN: Critique of success with methadone treatment. Am.J.Psychiat. 1972, 127:4:440-446.

27. PREBLE, E. & Th.MILLER: Methadone, wine and welfare. uit: R.S.Weppner (ed.): Street ethnography, Sage Publications, 1977.

28. HADDOX,V.G.& M.D.JACOBSON: Psychological adjustment - Mood and personality fluctuations of long term methadon maintenance patients. Intern.J.Addict. 1972, 7:4, 619-627.

29. FROMBERG,E., A.HAVAS & G.HAVERKAMP Jaarverslag Stichting Kontakt Sentra, Amsterdam, 1977.

30. PREBLE,E. & J.J.CASEY: Taking care of bussiness: the heroine user's life on the street. Uit: D.Smith & G.R.Gay (eds): It's so good, don't even try it once, Heroin in perspective. New Yersey, Prentice-Hall Inc. 1972.

31. ALEXANDER,B.K. & P.E.HADAWAY: Theories of opiate addiction: Time for pruning? J.Drug Issues, 1981;11:1.

32. SOLOWAY, I.H.:Methadon and the culture of addiction. J. Psychedelic Drugs 1974; 6:91-99.

33. NOORLANDER,E.: Intentional and unintentional effects of the Dutch methadone system. In Ch.D.Kaplan & M.Kooyman (eds): Proceedings of the 15th International Institute on the Prevention and Treatment of drugdependence of the I.C.A.A. Erasmus Universiteit, Rotterdam, 1987.

34. De MUG,W.: Heroine: een geneesmiddel of een genotmiddel. (T.Alc.Drugs, 1984, 10(4):171-173.

35. FROMBERG,E.: Moeten we het verdrag opzeggen? Aloha, 18,15-18.

36. VAN EPEN,J.H.: Compendium drugverslaving en alcoholisme. Elsevier, Amsterdam, 1978

37. ISBELL,H.: Addiction to barbiturates and the barbiturate abstinence syndrome, Ann.Int.Med., 1950,33,108

38. FREZZA M., PADOVA C. di, POZZATO G.: High blood alcohol levels

in women. New Engl. J. Med. 1990; 322; 95-99.

39. BLUM K., HAMILTON M.G., MEYER E.K.: Isoquinoline alkaloids as

possible regulators of alcohol addiction. Lancet 1977; I:799-800

40. JEFFCOATE W.J., et al.: Prevention of effects of alcohol intoxication by naloxone. Lancet, 1979, vol II:1157-1159

41. PAUL,S.: Science, 1986, vol. 234, blz. 1243 ev.

42. SUZDAK,P.D., GLOWA,J.R., CRAWLEY,J.N., SCHWARTZ,R.D., SKOLNICK,P. & PAUL,S.M.: A selective imidazobenzo-diazepine antagonist of ethanol in the rat. Science, 1986, vol. 234, blz. 1243-1247.

43. SCHUCKIT,M.A.: The importance of genetic factors in alcoholism. Drug abuse & alcoholism newsletter, 1989, vol. 18:1.

44. NEWLIN,D.B. & THOMSON,J.B.: Chronic tolerance and sensitization to alcohol in sons of alcoholics. Alcoholism: Clin. Exper. Res. 1991, 15:3; 399-405

45. HWANG,B.H.; LUMENG,L.; WU,J.-Y. & LI,T.-K.: Increased number of GABA-ergic terminals in the nucleus accumbens is associated with alcohol preference in rats. Alcoholism: clinical and experimental research 1990, 14:3, 503-507

46. UUSI-OUKARI,M. & KORPI,E.R.: Specific alterations in the cerebellar GABA-a receptors of an alcohol-sensitive ANT rat line. Alcoholism, Clin. Exper. Res. 1991 15:2; 241-248.

47. CRABB,D.W.: Molecular cloning in alcohol research. Alcohol health & Research world. 1990, 14:3; 197-203

48. Int.J.Drug Policy, 1990

49. JACKSON,J.G.: Letter; New Engl.J.Med. 1990. 321(13):907

50. MANTEGAZZA: Sulle virtue igieniche e medicinali della coca. Milano, Autoservazione, 1859

51. FREUD,S.: Uber Koka, Wiener zentralblatt fur die Gesamte Therapie, 1884; 2:289-314.

52. TORRES DE GALVIS,Y.: Current epidemiology and trends of cocaine use and abuse: an international review. The WHO, Geneva,October 1990.

53. GRINSPOON,L. & BAKALAR,J.: Cocaine, a drug and its social evolution. Basic Books, Inc., Publishers, New York, 1976.

54. SCOTT,P.D. & MARSHALL,J.: Cocaine politics. University of California Press, Berkeley, 1991

55. INCIARDI, J.A.: Letter, Int.J.Drug Policy, 1990, vol.1, nr 4 , blz. 26

56. WALDORF,D., MURPHY,S., REINARMAN,C. & JOYCE,B. Doing coke: an ethnography of cocaine users and sellers. 1977. Washington, D.C., Drug Abuse Council.

MURPHY,S., REINERMAN,C. & WALDORF,D.: An 11 year follow-up of a network of cocaine users. British Journal of Addictions, 1989; 84:427-436

57. ERICKSON,P.: A longitudinal study of cocaine users: the natural history of cocaine use and its consequences among Canadian adults. Toronto, Addiction Research Foundation. Final report NHRDP #6606-3929-DA, 1992.

58. COHEN,P.& SAS,A.: Ten years of cocaine. Department of Human Geography, University of Amsterdam, 1993

59. BROWN,R. & MIDDLEFELL,R.: Fifty five years of cocaine dependence. Br.J.Addictions 1989 vol. 84:8, 946.

60. New Scientist 17 nov. 1990

61. KOSTEN, T.R. et al.: Desipramine and its 2-hydroxy-metabolite in patients taking or not taking methadone (letter) Am.J.Psychiatry 1990; 147(10):1379-1380.

62. NEWCOMBE,R. & MATTHEWS,L.: Crack in Liverpool. Druglink, sept. okt. 1989, blz.16.

63. CHEUNG,Y.W.,ERICKSON,P.G. & LANDAU,T.C.: Experience of crack use: findings from a community-based sample in Toronto. J.Drug Issues, 1991; 21(1):121-140.

64. MAHALIK et al.: Teratogenic potential of cocaine-hydrochloride in CF-1 mice. J.Pharm. Sci. 1980;69:703-706

65. ACKER et al.: Abruptio placentae associated with cocaine use. Am J Obstet Gynecol 1983;146:220-221

66. CHASNOFF,I.J., BURNS,W.J., SCHNOLL,S. & BURNS,K.A.: Cocaine use in pregnancy, New England Journal of Medicine, 1985, 313 pp. 666-669

67. CHASNOFF,I.J., BUSSEY,M.E., SAVICH,R. & STACK,C.M.: Perinatal cerebral infarction and maternal cocaine use. Journal of Pediatrics, 1986, 108: 456-459

68. CHASNOFF,I.J. Perinatal effects of cocaine, Contemporary Obstetrics and Gynecology, May 1987 pp 163-179

69. CHASNOFF,I.J., BURNS,K.A. & BURNS,W.J.: Cocain use in pregnancy: perinatal morbidity and mortality. Neurotoxicology and Teratology, 1987; 161(9) pp. 291-293

70. CHASNOFF,I.J., CHISUM,G.M. & KAPLAN,W.E.: Maternal cocaine use and genitourinary tract malformations, Teratology 1988; 37:201-204

71. CHASNOFF,I.J., GRIFFITH,D., MacGREGOR,S., DIRKES,K. & BURNS,K.A.: Temporal patterns of cocaine use in pregnancy: perinatal outcome. Journal of the American Medical Association, 1989; 261(12)pp. 1741-1744

72. CHASNOFF,I.J., HUNT,C.E. & KAPLAN,D.: Prenatal cocaine exposure is associated with respiratory pattern abnormalities. American Journal of Diseases of Children, 1989; 143:583-587

73. KOREN,G., GRAHAM,K., SHEAR,H. & EINARSON,T.: Bias against the null hypothesis: the reproductive hazards of cocaine. Lancet 1989; no 8677, pp. 1440-1442

74. FROMBERG,E.: Cocaine and pregnacy, hype or science; a review of the literature. Background paper for meeting of WHO's Global Advisory Committee on Cocaine, August 1992.

75. LUTIGER,B., GRAHAM,K., EINARSON,T.R. & KOREN,G. (1991) Relationship between gestational cocaine use and pregnancy outcome: a meta-analysis. Teratology, 1991; 44(4) pp. 405-414.

76. SHULGIN,A.: The narcotic pepper - the chemistry and pharmacology of Piper methisticum and related species. Bull.Narc. 1973, 25(2):59-74.

77. LEWIN 1927, cit. P.d'ABBS : Kava use in Arnhemland, the challenge for policy. Internat.J.Drug Policy, 1991, 2(4).

78. SCHOPEN,A.: Das Qat. Geschichte und Gebrauch des Genussmittels Catha edulis (Forsk.) in der Arabischen Republik Jemen. Wiesbaden, 1978.

79. KENNEDY,J.G.: The flower of paradise: the institutionalised use of the drug qat in North Yemen. Reidel, Dordrecht, 1987.

80. BIRKENHÄGER,T.K., BRUIJN,J.A., NOLEN,W.A. & VEGT,M.: MAO-remmers als antidepressiva, een literatuuroverzicht betreffende indicatiegebied en werkingsmechanisme. Tijdschrift voor Psychiatrie, 1991, 33(7);445-462.

81. GOLDMAN,M.J., GRINSPOON,L. & HUNTER-JONES,S.: Ritualistic use of fluoxetine by a former substance abuser. Am.J.Psychiatry 1990, 147(10):1377

82. STOLERMAN,I.: Nicotine on the brain. New Scientist, 3-11-1990; 33-35.

83. HOFMANN,A. Structur und Synthese der Halluzinogene. J.Mond.Pharm., 1970;13(3):187-205

84. GARDNER,E.L. & LOWINSON,J.: Marijuana's interaction with brain reward systems: update 1991. Pharmacology Biochemistry and Behavior 1991;40:571-580.)

85. MATHEW,R.J. & WILSON,W.H.: Acute changes in cerebral blood flow after smoking marihuana. Life sciences, 1993; 52:757-767.

86. ROBBE,H.W.J.: Influence of marihuana on driving. Rijksuniversiteit Limburg, 1994.

87. SHEDLER,J. & BLOCK,J. Adolescent drug use and psychological health: a longitudinal inquiry. American psychologist, 1990, 45:612-630)

88. GRINSPOON,L.: Marihuana reconsidered. Harvard University Press, 1971.

89. GRINSPOON,L. & BAKALAR,J.B.: In: Lowinson et al.: Substance abuse. A comprehensive textbook, pp 236-246. Raven press, New York, 1992.

90. GRINSPOON,L. & BAKALAR,J.B.: Marihuana, the forbidden medicine. Yale University Press, New Haven, 1993.

91. TUNVING,K., THUNLIN,S.O., RISBERG,j. & WARKENTIN,S.: Regional cerebral bloodflow in long term heavy cannabis use. Psychiatry research, 1986, 17:15-21.

92. FARRE-ALBALADEJO,M.: Complicaciones neurologicas de las toxicomanias. Archivos de Neurobiologia, 1989, 52 (suppl.I):143-148.

93. FEHR,K. & KALANT,H.: Long-term effects of cannabis on cerebral function: a review of the clinical and experimental literature. In: Cannabis and health hazards. Proceedings of an ARF/WHO meeting on adverse health and behavioral consequences of Cannabis use. Toronto, 1983)

94. KOLODNY,R.C., MASTERS,W.H., KOLODNY,R.M. & TORO,G.: Depression of plasma testosterone levels after chronic intensive marihuana use. New E.ng. J. Med. 1974, 290:872-874.

95. BLOCK,R.I., FARINPOUR,R. & SCHLECHTE,J.A.: Effects of chronic marijuana use on testosterone, luteinizing hormone, follicle stimulating hormone, prolactin and cortisol in men and women. Drug and Alcohol dependence, 1991; 28: 121-128.

96. ZUCKERMAN,B., FRANK,D.A., HINGSON,R., AMARO,H., LEVENSON,S.M., KAYNE,H, PARKER,S., VINCI,R., ABOAGYE,K., FRIED,L.E., CABRAL,H., TIMPERI,R. & BAUCHNER,H. (1989) Effects of maternal marijuana

and cocaine use on fetal growth. New England Journal of Medicine, 320(12) pp. 762-768)

97. FRIED,P.A., BUCKINGHAM,M. & VON KULMIZ,P.: Marihuana use during pregnancy and perinatal risk factors. Am.J.Obstet.Gynecol. 1983,144:922-924.

98. FRIED,P.A.,WATKINSON,B. & WILLAN,A.: Marihuana use during pregnancy and decreased length of gestation. Am.J.Obstet.Gynecol. 1984;150:23-27.

99. FRIED,P.A.: Cigarettes and marihuana: are there measurable long term neurobehavioral teratogenic effects? Neurotoxicology 1989;10:577-583.

100. HOFFMAN,A.: LSD, my problem child. Tarcher, Los Angeles, 1983.

101. STEVENS,J.: Storming heaven: LSD and the American dream. New York, Atlantic Monthly Press, 1987.

102. MARTIAL,DE MONTIGNY et al."LSD ou Lysergide: pharmacologie et mecanismes d'action." Psychotropes 1988;4(3):7-11.

103. New Scientist 10-2-1983:367

104. COWAN, Intern.J.Quantum Chemistry, vol.22 p 1059 ev.

105. SILVERMAN: Research with psychedelics, Arch.Gen.Psychiat 1971;25:498-510.

106. SMITH & SEYMOUR: J.Psych. Drugs 17(4) pag 298 1985).

107. COHEN,S. & DITMAN,K.S.: Prolonged adverse reactions to LSD. Arch.Gen.Psychiatr. 1963, vol.8.).

108. FROMBERG.E.: Vondelparkproject 1972: verslag van de hulpverlening.Stadhuis Amsterdam, 1972).

109. COHEN,S.: Drug Abuse and Alcoholism vol VIII, no 2, 1979.

110. COHEN,S.: LSD:The varieties of psychotic experience, J.Psych.Drugs 17(4): 291-296 1985.

111. AMAROSE & SCHUSTER: Arch.Gen.Psychiatr. 1971; 25:181-186.

112. LEWIN,L.: Phantastica, 2e druk, Verlag G.Stilke, Berlin, 1927.

113. HUXLEY,A.: The doors of perception. Chatto & Windus, 1954. Heaven and hell. Chatto & Windus, 1956

114. MERCK,E.: Verfahren zur Darstellung von Alkyloxyaryldialyloxyaryl- und Alkylenedioxyarylaminopropanen bzw. deren am Stickstoff monoalkylierten Derivaten. Duits patent #274.350. 1914.

115. HARDMAN,H.F.; HAAVIK,C.O. & SEEVERS,M.H.: Relationship of the structure of mescaline and seven analogs to toxicity and behavior in five species of laboratory animals. Toxicology and Applied Pharmacology 1973; 25(2): 299-309.

116. GASTON, T.R. & RASMUSSEN, G.T.: Identification of 3,4-Methylenedioxymetamphetamine. Microgram 1972; 5:60-63

117. SHULGIN,A.T. & NICHOLS,D.E.: Characterization of three new psychotomimetics. In: Stillman,R.C. & Willette,R.E. (Eds.) The Pharmacology of hallucinogens. New York: Pergamon, 1978.

118. GREER,G. & STRASSMAN,R.J.: Information on "Ecstasy". Am.J.Psychiat. 1985; 142(11):1391

119. GREER,G. & TOLBERT,R.: Subjective reports of the effects of MDMA in a clinical setting. J. Psychoactive Drugs 1986, 18(4):319-327.

120. SEYMOUR,R.B.: MDMA, another view of Ecstasy. Pharmchem Newsletter 1985; 14(3):1

121. PEROUTKA,S.J.: Incidence of recreational use of 3,4-methylenedioxy-methamfetamine (MDMA,Extacy) on an undergraduate campus. N.Engl.J.Med.; 1987; 317: 1542-1543.

122. FROMBERG,E. & JANSEN,F.: Het Drug Informatie en Monitoring Systeem, verslag sept.'92-juni '93. NIAD, Utrecht, 1993.

123. SHULGIN,A.: Some qualitative properties of the psychotomimetics. Neurosciences Research Progress Bulletin 1970, 8(1):72-78

124. SHULGIN,A. & SHULGIN,A.: PIHKAL. Transform press, Berkeley, 1991

125. KLEIN,J.: The new drug they call Ecstasy. **New York, May 20,1985.

126. DOWNING,J.: The psychological and physiological effects of MDMA on normal volunteers. J.Psychoactive Drugs, 1986, 18(4): 335-340.

127. HAYNER, G.N. & McKINNEY, M.C.: The dark side of ecstacy. J. Psychoactive Drugs, 1986, vol.18(4): 341-347.

128. SEYMOUR,R.B.: MDMA, another view of Ecstasy. Pharmchem Newsletter, 1985, 14(3):1.

129. WOLFSON,P.E.: Meetings at the edge with Adam: a man for all seasons. J. of Psychoactive Drugs, 1986, vol. 18 (4):329-333

130. DE LOOR,A.: De drug XTC bestaat niet. Adviesburo Drugs, Amsterdam, 1989.

131. VEREBEY,K.,ALRAZI,J. & JAFFE,H.: The complications of "Ecstasy". JAMA, 1988; 259:1649-1650

132. BROWN,C. & OSTERLOH,J.: Multiple severe complications from recreational ingestion of MDMA ("Ecstasy"). JAMA 1987; 258: 780-781.

133. BRUSSEL,G.H.A.van,: XTC, een nieuwe softdrug. Ned.Tijdschrift v Geneeskunde: 1991, 135(44): 2062-2063

134. CREIGHTON,F.J., BLACK,D.L.& HYDE,C.E.: Ecstasy psychosis and flashbacks; British Journal of Psychiatry 1991, 159(11):713-715)

135. DOWLING,G.P.,McDONOUGH,E.T.& BOST,R.O.: "Eve" and "Ecstasy", a report of five deaths associated with the use of MDEA and MDMA. JAMA, 1987; 257(12): 1615-1617.

136. HENRY,J.A., JEFFREYS,K.J. & DAWLING,S.: Toxicity and deaths from 3,4-methylenedioxymethamphetamine ('ecstasy'). Lancet 1992; 340:384-387

137. MAN,R.A.de, WILSON,J.H.P. & TJEN,H.S.L.M.: Acuut lever-falen door methyleendioxymetamfetamine ('ecstasy'); NTVG 1993; 137(14): 727-729

138. McGUIRE,P. & FAHY,T.: Chronic paranoid psychosis after misuse of MDMA ('ecstasy"); BMJ, 1991, 302(6778):697

139. SCHIFANO,F.: Chronic atypical psychosis associated with MDMA ('ecstasy') abuse; Lancet 1991, 338:1335

140. SCREATON,G.R., SINGER,M., CAIRNS,H.S., THRASHER,A., SARNER,M. & COHEN,S.L. Lancet, 1992,339: 677-678

141. VEREBEY,K. & ALRAZI,J. & JAFFE,H.: The complications of "Ecstacy" (MDMA). JAMA, 1988; 259: 1649-1650.

142. WHITAKER-AZMITIA,P.M. & ARONSON,T.A.: "Ecstasy" (MDMA)-induced panic. Am.J.Psychiatry, 1989; 146(1): 119.

143. WINSTOCK,A.R.: Chronic paranoid psychosis after misuse of MDMA; British Medical Journal, 1991, 302(6785):1150-1151

144. GINZBERG,M.D., HERTZMAN,M. & SCHMIDT-NOWARA,W.W.: Amphetamine intoxication with coagulopathy, hypertehermia and reversible renal failure. Annals of Int.Med. 1970;73:81-85.

145. RICAURTE,G.A.,FORNO,L.S.,WILSON,M.A.,DELANNEY,L.E.,IRWINI.,MOLLIVER,M.E. & LANGSTON,J.: 3,4-Methylenedioxy-metamfetamine selectively damages central serotonergic neurons in non-human primates. JAMA; 1988; 260(1): 51-55

146. PRICE,L.H., RICAURTE,G.A.,KRYSTAL,J.H.& HENIGER,G.R.: Neuroendocrine and moodresponses to intravenous l-tryptophan in 3,4-methylenedioxymetamfetamine (MDMA) users. Arch.General Psychiatry, 1989, 46:20-22

147. McCANN,U.& RICAURTE,G.: presentation on the 1993 Annual Meeting of the Society for Neuroscience.

148. NICHOLS,D.E.: Differences between the mechanism of action of MDMA, MBDB and the classic hallucinogens. Identification of a new therapeutic entactogen class. J.Psychoactive Drugs, 1986; 18(4):305-313

149. EMBODEN,W.: Narcotic plants. Studio Vista, London,1972

150. Editorial: Ketamine a new anaesthetic. British Medical Journal 19-6-1971, pag. 666.

151. RAINEY,J.M. & CROWDER,M.K.: Ketamine or phencyclidine (letter). JAMA, 1974, 230(6): 824

152. Editorial: Phencyclidine, the new american street drug. British Medical Journal 1980;281:1511.

153. Various authors: J.Psychedelic drugs: 1980; 12(3&4):181-335

154. FROMBERG.E.: De samenstelling van illegale drugs in Nederland, Stichting DrugInformatie, Amsterdam, 1973

155. SHAPIRO,H.: Ketamine factsheet. Druglink 1992; 7(3):7

Tradução do texto disponível no Drugtext website.

Publicado com o consentimento da DrugText.

Junho de 1997

ser@mail.telepac.pt

Voltar à página principal